A surprise Keytruda approval, and what it means for biotech
A Her2-positive cancer is the setting for a Keytruda triplet that could influence the trial design of some immune-stimulating agents.
Biolinerx could mobilise interest in CXCR4 antagonism
A phase 3 win should remind investors about other clinical-stage CXCR4 antagonists.
Roivant rewrites the Spac script, again
After revealing plans to buy one of its holdings out of a Spac, Roivant itself moves towards a blank-cheque company listing.
